Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lebwohl

Showing results (301-310 of 418) with videos related to

Pageof 42
Sort By:
Dermatology and Therapy|October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)Jerry Bagel, John Nia, Peter W Hashim, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
Dermatology and Therapy|February 7, 2025
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis TrialsJoseph F Merola, Laura K Ferris, Jeffrey M Sobell, et al.
The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Dermatology and Therapy|December 11, 2025
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 YearDiamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus PanelMilaan Shah, Joshua Burshtein, Danny Zakria, et al.
The New England Journal of Medicine|November 25, 2003
A novel targeted T-cell modulator, efalizumab, for plaque psoriasisMark Lebwohl, Stephen K Tyring, Tiffani K Hamilton, et al.
Dermatology and Therapy|February 10, 2024
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Journal of Drugs in Dermatology : JDD|May 6, 2024
Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)Todd Schlesinger, Leon Kircik, Mark Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Advances and Considerations in the Management of Actinic Keratosis: An Expert Consensus Panel ReportJames Del Rosso, April W Armstrong, Brian Berman, et al.
Pageof 42

Showing results (301-310 of 418) with videos related to

Sort By:
Pageof 42
Dermatology and Therapy|October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)Jerry Bagel, John Nia, Peter W Hashim, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
Dermatology and Therapy|February 7, 2025
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis TrialsJoseph F Merola, Laura K Ferris, Jeffrey M Sobell, et al.
The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Dermatology and Therapy|December 11, 2025
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 YearDiamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus PanelMilaan Shah, Joshua Burshtein, Danny Zakria, et al.
The New England Journal of Medicine|November 25, 2003
A novel targeted T-cell modulator, efalizumab, for plaque psoriasisMark Lebwohl, Stephen K Tyring, Tiffani K Hamilton, et al.
Dermatology and Therapy|February 10, 2024
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Journal of Drugs in Dermatology : JDD|May 6, 2024
Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)Todd Schlesinger, Leon Kircik, Mark Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Advances and Considerations in the Management of Actinic Keratosis: An Expert Consensus Panel ReportJames Del Rosso, April W Armstrong, Brian Berman, et al.
Pageof 42